Some drug spending highlights:
- For 2018, spending on outpatient prescription drugs grew by 2.5%—below the spending growth rate on hospitals, physician services, and overall national healthcare costs.
- CMS significantly lowered its previously reported drug spending figures by billions after incorporating new data on manufacturers’ rebates.
Unfortunately, the share and amount that Americans are forced to pay of prescription drug spending is much greater than that of other healthcare services. This circumstance derives from benefit designs, not drug prices. See what you think in our pretty charts below.
Drug Channels Institute will host an exclusive live webinar, Drug Channels Outlook: What You Need to Watch in 2020, on Friday, December 13, 2019, from 12 p.m. to 1:00 p.m. ET. Get ready for what will certainly be another year of change for U.S. healthcare. CLICK HERE TO LEARN MORE AND SIGN UP.
If you register but can't make it this Friday, you'll receive a link to watch the replay.
I ♥ DATA
As always, I encourage you to review the CMS source materials:
- Health Affairs article: National Health Care Spending In 2018: Growth Driven By Accelerations In Medicare And Private Insurance Spending (The article is free for subscribers; others may purchase it.)
- National Health Expenditures data files (C’mon, have some fun!)
FOLLOW THE MONEY
As measured in the National Health Expenditures (NHE) accounts, total U.S. spending on healthcare was an astounding $3.6 trillion in 2018.
In keeping with previous years’ figures, spending on hospital care and professional healthcare services was more than six times higher than spending on outpatient prescription drugs:
- Nearly $2.2 trillion (59%) in total healthcare expenditures in 2018 came from hospital care and professional services (physicians, dentists, and other healthcare professionals). These categories’ shares have been consistent for many years.
- In 2018, U.S. net spending on outpatient prescription drugs was $335 billion. For 2018, prescription drugs accounted for only 9.2% of U.S. healthcare spending, having fallen from 9.9% share in 2015.
As we describe in the notes below, CMS has significantly reduced its private health insurance drug spending figures from 2007 through 2017. That’s one reason why drug spending now accounts for a lower share of national spending.
[Click to Enlarge]
Note that these drug spending data measure net, post-rebate spending on patient administered drugs that are paid under the pharmacy benefit. Inpatient prescription drug spending within hospitals and nearly all provider-administered outpatient drugs are reported within the hospital and professional services categories.
However, drug spending accounts for a very small share of these other categories. For example, Part B spending at hospitals accounted for less than 5% of Medicare’s $1.2 trillion in total payments to hospitals. (I discuss these data here: Part B Update: Hospitals Displacing Physicians, Amid Slow Growth in Drug Prices.)
Is it any wonder that hospitals and physicians often try to delegitimize the NHE as a measure of drug spending so as to shift blame to drugmakers for high healthcare spending?
Spending on outpatient prescription drugs in 2018 grew by 2.5%, compared with a (revised) 1.4% increase for 2017. The 2018 figure is still slower than overall national health expenditures, which increased by 4.6%.
For years, drug spending has been growing more slowly than the other major spending categories. The chart below compares the year-over-year change in outpatient retail prescription drug spending with growth in spending on hospital care and professional services. As you can see, drug spending has trailed the growth in these other two categories for seven of the past nine years.
[Click to Enlarge]
The only exceptions occurred in 2014 and 2015, due to strong growth in spending for drugs used to cure hepatitis C. The net, post-rebate costs for those drugs have plummeted due to competition—though patients don’t always benefit from these rebates.
This slow growth in drug spending is consistent with the data from the largest pharmacy benefit managers (PBMs) shown in Which PBM Best Managed Drug Spending in 2018: CVS Health, Express Scripts, MedImpact, or Prime Therapeutics?
CMS attributed the 2018 drug spending growth to utilization, not prices. Here’s an excerpt from its Health Affairs article:
“In 2018 faster growth in nonprice factors helped drive the increase in total retail prescription drug spending growth, while price growth for both generic and brand-name drugs slowed. The number of prescriptions dispensed (based on thirty days’ supply) increased 2.7 percent, which was faster than the 2017 growth rate of 1.8 percent … Retail prescription drug prices declined by 1.0 percent in 2018, reflecting a decline in generic drug prices and slower and relatively low growth in prices for brand-name drugs. Additionally, greater use of generic drugs in 2018 put downward pressure on prices, even though the change in the generic dispensing rate was the smallest since 2000—an increase of just 0.3 percentage points to 85.6 percent.”THE REAL STORY
American patients don’t care about such policy terms like “health expenditures” and “net drug price.”
Instead, patients care about their out-of-pocket spending. When people complain about “drug prices,” they are actually complaining about the share of costs that they pay—and how those costs are computed.
In 2018, consumers’ out-of-pocket expenses—cash-pay prescriptions plus copayments and coinsurance—accounted for 14% of spending and grew by only 0.6%. But as I note in Employer Pharmacy Benefits in 2019: High Deductibles and Greater Coinsurance Expose Even More Patients to Prescription List Prices, some patients end up paying a much greater share of costs due to pharmacy benefit designs.
Another unusual aspect of U.S. healthcare is the relative share of costs borne by patients for different services. For 2018, total U.S. spending on hospital care was more than $857 billion higher than prescription drug spending. However, consumers’ out-of-pocket spending for hospital care ($34.8 billion) was more than $12 billion lower than consumers’ out-of-pocket spending for outpatient prescriptions ($47.1 billion).
[Click to Enlarge]
The gross-to-net bubble plays an unfortunate part in this story, too. More than half of insured patients’ out-of-pocket prescription costs are tied to the list price, not the post-rebate net cost. See my comments in Half-Off Sale! Five Major Drugmakers Reveal Vast Gross-to-Net Price Gaps—and Why Rebate Reform Is Still Needed.
This benefit design discrepancy partly explains why consumers are so much more unhappy about prescription drug spending than they are about hospital spending. Of course, hospitals are starting to change this perspective by relentlessly suing poor patients. That’s not really a good thing.
Regular readers know the unofficial motto of Drug Channels: "Everyone is entitled to their own opinion, but not their own facts." Every year, I hope that the latest NHE data will bring balance to the public discussion of U.S. healthcare spending.
And every year, I’m disappointed.
NOTES FOR NERDS
- U.S. drug spending in the NHE is roughly equivalent to total retail, mail, long-term care, and specialty pharmacies’ prescription revenues minus manufacturer rebates to third-party payers. It therefore differs from pharmacies’ prescription revenues, manufacturers’ revenues, and the “invoice price spending” data reported by IQVIA.
- We define “Professional Care” to include these NHE categories: Physician and Clinical Services; Dental Services; and Other Professional Services.
- The NHE data do not measure total U.S. spending on prescription drugs. Inpatient prescription drug spending within hospitals and nearly all provider-administered outpatient drugs are reported in other categories. This spending accounts for an estimated additional 4% to 5% of national expenditures.
- Note that CMS substantially revised the NHE drug spending figures from 2007 through 2017. In its methodology paper, CMS attributed the revisions to a new data for computing the value of rebates in private health insurance. For example, net spending on prescription drugs by private health insurance is now reported to have been $133.8 billion in 2016. That’s $10.8 billion lower (-7%) than the previously reported figure. The chart below summarizes the differences.
[Click to Enlarge]